Ovarian Cancer Trial Result:
Improved response to previously failed traditional therapies
Exposure to a medically induced high fever, under the HEATT® procedure, stimulates innate immune pathways as indicated by cytokine signaling. This upregulation of the immune response contributes to the body’s defenses which attacks remaining cancer cells. Data collected from autopsy showed tumor infiltration by lymphocytes in the ovarian trial and implies this process as a benefit of HEATT®.
All patients who agreed to be treated in the HEATT® study had already exhausted all traditional therapies that were available at the time the study was initiated. Based on survival times identified in the Hanker study, patients were expected to live eight months or less. After HEATT®, seven of the ten patients in the study were able to restart additional lines of therapy, which prior to HEATT® had not prevented disease progression. These additional treatments included localized hyperthermia, radiation therapies, and chemotherapies. These seven patients experienced a significant increase in life expectancy, living over eighteen months longer than predicted by the Hanker study. The opportunity to restart prior lines of therapy, resulting in significantly longer survival, was not expected when the patients entered the study. The increase in survival suggests a possible reset of a molecular mechanism known as thermal sensitization which may make the cancer cells more sensitive to traditional chemotherapies.